Statins Do Not Directly Inhibit the Activity of Major Epigenetic Modifying Enzymes

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Apr 13

PMID 30974899

Citations 7

Authors

Stephanie Bridgeman

Wendy Northrop

Gaewyn Ellison

Thiru Sabapathy

Phillip E Melton

Philip Newsholme

Cyril D S Mamotte

Affiliations

Soon will be listed here.

Abstract

The potential anticancer effects of statins-a widely used class of cholesterol lowering drugs-has generated significant interest, as has the use of epigenetic modifying drugs such as HDAC and DNMT inhibitors. We set out to investigate the effect of statin drugs on epigenetic modifications in multiple cell lines, including hepatocellular carcinoma, breast carcinoma, leukemic macrophages, cervical adenocarcinoma, and insulin-secreting cells, as well as liver extracts from statin-treated C57B1/6J mice. Cells or cell extracts were treated with statins and with established epigenetic modulators, and HDAC, HAT, and DNMT activities were quantified. We also examined histone acetylation by immunoblotting. Statins altered neither HDAC nor HAT activity. Accordingly, acetylation of histones H3 and H4 was unchanged with statin treatment. However, statins tended to increase DNMT activity. These results indicate that direct inhibition of the major classes of epigenetic modifying enzymes, as previously reported elsewhere, is unlikely to contribute to any anticancer effects of statins. This study concerned global effects on epigenetic enzyme activities and histone acetylation; whether statins influence epigenetic modifications in certain genomic regions, cannot be ruled out and remains to be investigated.

Citing Articles

Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells.

Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S Sci Adv. 2024; 10(23):eadj7706.

PMID: 38848360 PMC: 11160475. DOI: 10.1126/sciadv.adj7706.

Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease.

Xi C, Palani C, Takezaki M, Shi H, Horuzsko A, Pace B Antioxidants (Basel). 2024; 13(3).

PMID: 38539870 PMC: 10968127. DOI: 10.3390/antiox13030337.

Current Approaches to Epigenetic Therapy.

Griazeva E, Fedoseeva D, Radion E, Ershov P, Meshkov I, Semyanihina A Epigenomes. 2023; 7(4).

PMID: 37873808 PMC: 10594535. DOI: 10.3390/epigenomes7040023.

Unraveling the Anticancer Potential of Statins: Mechanisms and Clinical Significance.

Zaky M, Fan C, Zhang H, Sun X Cancers (Basel). 2023; 15(19).

PMID: 37835481 PMC: 10572000. DOI: 10.3390/cancers15194787.

Butyrate Lowers Cellular Cholesterol through HDAC Inhibition and Impaired SREBP-2 Signalling.

Bridgeman S, Woo H, Newsholme P, Mamotte C Int J Mol Sci. 2022; 23(24).

PMID: 36555149 PMC: 9779842. DOI: 10.3390/ijms232415506.

References

Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem H, Zielenkiewicz P . Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005; 65(14):6305-11. DOI: 10.1158/0008-5472.CAN-04-2957. View

Lin Y, Lin J, Chou C, Chang Y, Yeh S, Chen C . Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 2008; 68(7):2375-83. DOI: 10.1158/0008-5472.CAN-07-5807. View

Codd R, Braich N, Liu J, Soe C, Pakchung A . Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol. 2008; 41(4):736-9. DOI: 10.1016/j.biocel.2008.05.026. View

Liu Z, Xie Z, Jones W, Pavlovicz R, Liu S, Yu J . Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2008; 19(3):706-9. DOI: 10.1016/j.bmcl.2008.12.041. View

Jove M, Serrano J, Bellmunt M, Cassanye A, Angles N, Reguant J . When cholesterol is not cholesterol: a note on the enzymatic determination of its concentration in model systems containing vegetable extracts. Lipids Health Dis. 2010; 9:65. PMC: 2901322. DOI: 10.1186/1476-511X-9-65. View

Ordovas J, Smith C . Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010; 7(9):510-9. PMC: 3075976. DOI: 10.1038/nrcardio.2010.104. View

Bjorkhem-Bergman L, Lindh J, Bergman P . What is a relevant statin concentration in cell experiments claiming pleiotropic effects?. Br J Clin Pharmacol. 2011; 72(1):164-5. PMC: 3141200. DOI: 10.1111/j.1365-2125.2011.03907.x. View

Kodach L, Jacobs R, Voorneveld P, Wildenberg M, Verspaget H, van Wezel T . Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut. 2011; 60(11):1544-53. DOI: 10.1136/gut.2011.237495. View

Kanwal R, Gupta S . Epigenetic modifications in cancer. Clin Genet. 2011; 81(4):303-11. PMC: 3590802. DOI: 10.1111/j.1399-0004.2011.01809.x. View

10.

Feig J, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, Shamir R . Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One. 2011; 6(12):e28534. PMC: 3232231. DOI: 10.1371/journal.pone.0028534. View

11.

Naci H, Brugts J, Fleurence R, Tsoi B, Toor H, Ades A . Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013; 20(4):641-57. DOI: 10.1177/2047487313480435. View

12.

Chen J, Chern T, Wei T, Chen C, Lin J, Fang J . Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem. 2013; 56(9):3645-55. DOI: 10.1021/jm400179b. View

13.

Johansen M, Green L, Sen A, Kircher S, Richardson C . Cardiovascular risk and statin use in the United States. Ann Fam Med. 2014; 12(3):215-23. PMC: 4018369. DOI: 10.1370/afm.1641. View

14.

Aiman U, Najmi A, Khan R . Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014; 5(3):181-5. PMC: 4156828. DOI: 10.4103/0976-500X.136097. View

15.

Burgio E, Lopomo A, Migliore L . Obesity and diabetes: from genetics to epigenetics. Mol Biol Rep. 2014; 42(4):799-818. DOI: 10.1007/s11033-014-3751-z. View

16.

Tikoo K, Patel G, Kumar S, Karpe P, Sanghavi M, Malek V . Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol. 2014; 93(3):343-51. DOI: 10.1016/j.bcp.2014.11.013. View

17.

Mottamal M, Zheng S, Huang T, Wang G . Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015; 20(3):3898-941. PMC: 4372801. DOI: 10.3390/molecules20033898. View

18.

Karlic H, Thaler R, Gerner C, Grunt T, Proestling K, Haider F . Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genet. 2015; 208(5):241-52. PMC: 4503872. DOI: 10.1016/j.cancergen.2015.03.008. View

19.

Kavalipati N, Shah J, Ramakrishan A, Vasnawala H . Pleiotropic effects of statins. Indian J Endocrinol Metab. 2015; 19(5):554-62. PMC: 4566334. DOI: 10.4103/2230-8210.163106. View

20.

Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W . Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2016; 140(5):1068-1081. DOI: 10.1002/ijc.30526. View